Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Argenx Se ( (ARGX) ).
On November 18, 2025, argenx SE announced the approval of its remuneration policy during the Extraordinary General Meeting of shareholders. The policy was approved by a 95.67% majority, with 91.1% of share capital represented, highlighting strong shareholder support and potentially impacting the company’s governance and stakeholder relations.
The most recent analyst rating on (ARGX) stock is a Buy with a $1124.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
argenx is a global immunology company focused on developing and commercializing novel antibody-based medicines for severe autoimmune diseases. Through its Immunology Innovation Program, argenx collaborates with academic researchers to advance its portfolio, including the first approved neonatal Fc receptor (FcRn) blocker.
Average Trading Volume: 364,155
Technical Sentiment Signal: Buy
Current Market Cap: $55.65B
For detailed information about ARGX stock, go to TipRanks’ Stock Analysis page.